Author of

• 28120

  +

  Poster Session (ID 8)

  • Event: ACLC 2018
  • Type: Poster Session
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall

  • 28167

    +

    P113 - Icotinib Alone or with Radio Therapy Inpatients with EGFR Mutations Non-Small Cell Lung Cancer Who Develop Brain Metastases (ID 120)

    00:00 - 00:00  |  Author(s): Y. Xin
    • Abstract

    Background:
    To retrospectively analyze the efficacy and prognostic factors of ectinib hydrochloride alone or combined with brain radiotherapy in the treatment of brain metastases from NSCLC with EGFR mutation, so as to provide a reference for more accurate evaluation of prognosis and selection of the best treatment modality.
    
    
    Method:
    Total of 85 patients were enrolled from Oct/2014 to Oct/2017 in JLCH who pathologically diagnosed or cytology for NSCLC with EGFR mutations and had developed brain metastases. All the 85 patients were adenocarcinoma. 51 patients received with icotinib combined radiotherapy. 34 patients received with Icotinib alone, 15 patients took loca lesion radiotherapy, 11 patients took whole brain radiation therapy, 25 patients took whole brain radiation therapy and plus dose. SPSS22.0 was applied for survival analysis with Kaplan-Meier method and categorical data with chi-square test. COX model for multiple factors analysis. Logistic method for RR and DCR multi-factor analysis.
    
    
    Results:
    The total iORR is 64.6%, the iDCR is 95.3%. For the group of icotinib alone, iCR is 5 (14.7%), iPR is 14 (41.2%), iSD is 10 (29.4%), and iPD is (14.7%). iORR is 55.9%, iDCR is 85.2%. For the group of icotinib combined radiotherapy, iCR is 5 (9.8%), iPR is 29 (56.9%), iSD is 17 (33.3%). iORR is 66.7%, iDCR is 100%. There were statistical difference for iDCR between two groups (?2=7.698, P=0.022). Logistic model multi-factor analysis results: the surgery history of pulmonary lesion, Update-GPA grading scale and the number of metastasis organs were OS independent factors, the time to brain metastasis, mutation type and Update-GPA grading scale were PFS independ- ent factors, the time to brain metastasis, mutation type and Update-GPA grading scale were iPFS independent factors. The iDCR of the group of loca lesion radiotherapy, the whole brain radiation therapy and local acceleration were 100%, the iORR is 53.8%, 77.8%, 70.0%. The iDCR of the group of the early involvement of radiotherapy is 100%, the iORR is 77.8%, 46.7%, there were statistical difference between two groups (?2=4.200, P=0.040).
    
    
    Conclusion:
    1. The use of Icotinib to EGFR mutant NSCLC patients with brain metastases have a higher intracranial objective response rate, prolonged survival significantly. 2. The history of pulmonary lesion surgery, update-GPA grading scale and the number of metastasis organs were OS independent factors, the time to brain metastasis, mutation type and update-GPA grading scale were PFS and iPFS independent factors. 3. The participation of brain radiotherapy can increase iDCR. The early participation of brain radiotherapy can increase iORR.